India, April 4 -- New research to be presented at the European Congress on Obesity 2026 (ECO 2026, Istanbul, Turkey, May 12-15) reveals that individuals living with Obstructive Sleep Apnea (OSA) face a 71% higher risk of cardiovascular events (CVEs) or death from any cause compared to those without the condition.

The study is a collaboration between Imperial College Health Partners, Imperial College Healthcare NHS Trust, and Eli Lilly and Company, which also sponsored the research. The company manufactures obesity and diabetes treatments, including tirzepatide.

OSA is characterised by repeated upper airway obstruction during sleep, leading to poor sleep quality, reduced quality of life, and increased cardiovascular risk. Between 40% and...